Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Asthma jab gains approval

  • Comment
NICE has approved omalizumab (Xolair), a fortnightly injection that could halve acute exacerbations of allergic asthma in adults and children over 12 years.

NICE has approved omalizumab (Xolair), a fortnightly injection that could halve acute exacerbations of allergic asthma in adults and children over 12 years.

The institute said it should only be used if the asthma was severe and unstable despite other efforts to control it, and should be used alongside current asthma medications. If unsuccessful after 16 weeks, it should be stopped.

Final guidance has also been issued on inhaled corticosteroid use for chronic asthma in children under 12. For details see www.nice.org.uk

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs